Daewoong Pharmaceutical, Pexuclu 1st Anniversary Event "Annual Sales Target of 100 Billion Won"

"P-CAB Market Leading Treatment"
CEO Lee Chang-jae "Annual Sales Target 100 Billion Won"

Daewoong Pharmaceutical announced on the 5th that it has concluded the 'Pexuclu Week,' the first anniversary event for the gastroesophageal reflux disease (GERD) new drug 'Pexuclu' (active ingredient: Pexuprazan Hydrochloride), which was launched on July 1st last year.

Participants are taking a commemorative photo at the ceremony held to celebrate the 1st anniversary of the release of Paxclu.
[Photo by Daewoong Pharmaceutical]

The event, held both online and offline for a week from the 26th of last month to the 2nd, was attended by over 12,000 medical professionals from various departments including gastroenterology and cardiology, who shared the latest trends in prescribing Pexuclu and its unique advantages in clinical practice.

Pexuclu, a potassium-competitive acid blocker (P-CAB) developed independently by Daewoong Pharmaceutical for the treatment of GERD, is a next-generation therapy that improves upon the drawbacks of existing proton pump inhibitors (PPIs), such as slow onset of action and dietary influences. In less than a year since its launch, Pexuclu has surpassed cumulative sales of 30 billion KRW and is showing growth in both domestic and international markets, having expanded to 18 countries overseas.

At the final event of Pexuclu Week, the '1st Anniversary Offline Symposium' held from the 1st to the 2nd, medical professionals gave positive evaluations. Professor Seo Seung-in of the Department of Gastroenterology at Gangdong Sacred Heart Hospital, who presented in the session titled 'Clinical Application Results of Pexuclu in Gastroesophageal Reflux Disease,' stated, "Pexuclu has a rapid effect and the longest half-life of 9 hours among GERD medications. With just once-daily dosing, it can significantly improve nighttime acid secretion symptoms, enhancing patient medication compliance."

Following this, Professor Ahn Ji-yong of the Department of Gastroenterology at Seoul Asan Medical Center, who presented on 'The Effectiveness of P-CAB Agents in Helicobacter Eradication Therapy,' explained, "Although more specific clinical data need to be secured, based on recent P-CAB research results on Helicobacter eradication, Pexuclu is expected to play an increasingly important role in eradication therapy requiring strong effects at pH levels above 6."

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "The first anniversary event of Pexuclu, which has successfully established itself in the GERD market, was able to conclude successfully thanks to everyone's enthusiastic interest. Starting with the full-scale challenge to surpass annual sales of 100 billion KRW, Daewoong Pharmaceutical will continue to strengthen Pexuclu's solid advantages and nurture it as a 'game changer' to shift the treatment paradigm in the domestic and international GERD markets from PPI to P-CAB."

A cake cutting ceremony is taking place at the Pexuclu Week event celebrating the 1st anniversary of Pexuclu's launch. From the left are Professors Hyunduk Shin of Dankook University Hospital, Jaegyu Kim of Chung-Ang University Hospital, Hyojin Park of Gangnam Severance Hospital, Myungkyu Choi of Seoul St. Mary's Hospital, Nayoung Kim of Bundang Seoul National University Hospital, and Chanhyuk Park of Hanyang University Guri Hospital.
[Photo by Daewoong Pharmaceutical]

This content was produced with the assistance of AI translation services.